Global Pharma Drug Regulatory Affairs course

we have seen contens of course

In this session we have learned about the career oportunities in Regulatory affairs.

Regulatory Affairs Specialists assist in obtaining and maintaining government approval for drugs, medical devices, nutritional products, and related materials. They are often employed by pharmaceutical, biotechnology, and medical device companies. They may also work in government or law.

Careers in Regulatory Affairs

There is a wide variety of careers in the regulatory affairs field. Regulatory professionals carry titles such as:

• Regulatory affairs specialist

• Regulatory affairs manager

• Regulatory affairs director

• Compliance specialist

• Food safety inspector

• Clinical research associate

• Director of quality assurance

These regulatory professionals play a critical role in the development and distribution of medical technological advancements and disease-free food, improving people’s health and welfare around the world.

What do regulatory affairs professionals earn?

Much like the setting and scope of a regulatory job, regulatory salaries vary, depending on job function, previous regulatory experience, seniority, geographic market, and highest earned degree.

And as market demand has increased, employers are willing to pay more for the right level of skill. Since 1995, salaries across all regulatory professions have maintained a general upward trend, increasing by an average of 3.3 percent per year. As of 2016, the average yearly salary for regulatory professionals at all levels was $150,422.

According to the Regulatory Affairs Professional Society’s (RAPS) 2018 report, the national average total compensation for U.S.-based regulatory professionals by job level is:

• Vice President: $256,500

• Director: $189,000

• Manager: $139,000

• Project Manager: $128,000

• Specialist: $123,000

• Associate: $93,000

So Look for Course description & Look for see you in the class.

In this session we have seen about Introduction and objectives of this course. general regulatory aspects and basic consepts in RA.

Regulatory affairs (RA) professionals play critical roles in a pharmaceutical industry because it is concern about the healthcare product lifecycle, it provide Strategic, Tactical and Operational direction and support for working within regulations to expedite the development and delivery of safe and effective healthcare products to individuals around the world.

The detailed will be shown in further sessions.

According to Stephen Amato, PhD, associate teaching professor, and lead faculty member for Northeastern’s Master of Science in Regulatory Affairs program, the answer is, “It depends.”

Because the field of global regulatory affairs spans a diverse set of disciplines, including law, economics, public policy, health, and science, the scope of a regulatory professional’s work varies. Career paths and daily responsibilities may differ based on areas of expertise, but all regulatory professionals have one goal in common: to facilitate the commercialization of safe and effective products and services. Some regulatory affairs professionals manage clinical studies or develop marketing approval policies, while others design labels for food- and drug-related products.

One of the most common titles in the industry is regulatory affairs specialist. These specialists analyze new and existing regulations in relation to an organization’s products or processes. They also review marketing, legal, and technical documentation, including case files and clinical research reports, to assess compliance with global regulatory agency policies, regulations, and standards. Regulatory affairs specialists may also recommend courses of remediation to help companies achieve the necessary levels of compliance. Acting as a liaison between manufacturing organizations and federal agencies, they may be responsible for submitting critical regulatory documents, with the goal of approval for sale and distribution.

Senior-level regulatory professionals often make strategic business decisions that have significant legal and financial repercussions. A large part of a regulatory affairs role, at all levels, is to interpret and communicate these implications to a diverse set of internal and external stakeholders.

Regulatory professionals are also often a voice in conversations at the cutting edge of health and public policy. Darin Detwiler, PhD, assistant dean, and director of Northeastern’s Master of Science in the Regulatory Affairs of Food and Food Industries program, says that regulatory work is more than a job; it’s a mission.

He says his goal as a regulatory leader and educator, “is not just to send students forth with degrees, but to build effective leaders and change agents in the health and food industries. [Regulatory work] is a big part of the solution to major public health and food safety challenges.”

In this session we have seen about websites and their how to use during work in RA.

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is unique in bringing together the regulatory authorities and pharmaceutical industry to discuss scientific and technical aspects of pharmaceuticals and develop ICH guidelines.

Since its inception in 1990, ICH has gradually evolved, to respond to increasingly global developments in the pharmaceutical sector and these ICH guidelines are applied by a growing number of regulatory authorities. ICH's mission is to achieve greater harmonisation worldwide to ensure that safe, effective and high quality medicines are developed, and registered and maintained in the most resource efficient manner whilst meeting high standards

In this session we have seen about Basics consepts in ICH guidlines.

Literature survey required for both Researcher and RA professionals during there work.

In this session students will learn about online literatures. How to use websites and which information is available on online for Drug development of Pharmacetical products and Regulatory Compliance.

DMF stands for Drug Master File which contains confidential information related to the manufacturing, control or chemistry of the product.

US DMF filing is the provision made by the US FDA to maintain the confidentiality of the information in the DMF Filing. The Manufacturer of the Drug, excipient, or packaging material can directly submit the product related confidential information to the FDA without disclosing the information to their customer. However, the manufacturer may have to disclose parts of the DMF such as product specifications and general information to their customer, since such information is mandatory for product development and quality control related activities.

Facts about FDA DMF

• DMF filing is not mandatory

• DMF filing is the provision to submit the information directly to FDA without disclosing the information to your customer.

• DMFs are neither approved nor disapproved. FDA reviews the DMF against drug applications in which those DMFs are referred.

• FDA DMF number does not constitute FDA approval

Drug Master File holders must submit an amendment if there are any changes in the DMF and submit a report annually.

FDAbasics offer services for DMF filing services including DMF amendments and annual reports.

Students learned about Difference between Drug Master File and Various Application.

Students learned about submission of DMF. Also closing of DMF

Module 1 of the CTD describes the administrative information and prescribing information (for example, the application form, the proposed product information and labelling)

Advantages of the eCTD structure:

• Reviewers are already familiar with the content and document standards

• Local affiliates can review updates in real-time

• FDA reviewers can review faster and more efficiently, shortening time to approval

• Handling, managing, and archiving trial and document-essential information is less time-consuming

• Documents are easily accessible via search and tracking

• The risk of missing or duplicated documents is minimized

Module 2 contains the CTD overviews and sum- maries. It starts with a general introduction to the. drug, including its pharmacological class, mode of. action, and proposed clinical use.

CTD Module 3 is the section of the common technical document (CTD) regulatory submissions format that contains all the required quality information and data corresponding to the registration of a pharmaceutical product.

CTD Module 3 is well defined containing both drug substance (active ingredient) and drug product sections, with each containing required presentations of drug technical information, processes and key parameters, and various justification supported by qualification and validation studies.

This data and these reports provide the detailed evidence that a drug’s characteristics are well defined and well controlled, such that one can assure that the next lot produced is essentially the same as the last lot. Drug manufacture control and reproducibility is the essential message that Module 3 must convey if Agency reviewers are to conclude that a new drug application merits approval.

Module 4 describes the format and organisation of the nonclinical (pharmaco-toxicological) data relevant to the application

Module 5 contains all of the clinical study report data needed to support the application and to

demonstrate that the generic drug product is bioequivalent to the RLD.

Introduction

For decades, the regulation and control of new drugs in the United States has been based on the New Drug Application (NDA). Since 1938, every new drug has been the subject of an approved NDA before U.S. commercialization. The NDA application is the vehicle through which drug sponsors formally propose that the FDA approve a new pharmaceutical for sale and marketing in the U.S. The data gathered during the animal studies and human clinical trials of an Investigational New Drug (IND) become part of the NDA.

The goals of the NDA are to provide enough information to permit FDA reviewer to reach the following key decisions:

• Whether the drug is safe and effective in its proposed use(s), and whether the benefits of the drug outweigh the risks.

• Whether the drug's proposed labeling (package insert) is appropriate, and what it should contain.

• Whether the methods used in manufacturing the drug and the controls used to maintain the drug's quality are adequate to preserve the drug's identity, strength, quality, and purity.

The documentation required in an NDA is supposed to tell the drug's whole story, including what happened during the clinical tests, what the ingredients of the drug are, the results of the animal studies, how the drug behaves in the body, and how it is manufactured, processed and packaged. The following resources provide summaries on NDA content, format, and classification, plus the NDA review process

Guidance Documents for NDAs

Guidance documents represent the Agency's current thinking on a particular subject. These documents are prepared for FDA review staff and applicants/sponsors to provide guidelines to the processing, content, and evaluation/approval of applications and also to the design, production, manufacturing, and testing of regulated products. They also establish policies intended to achieve consistency in the Agency's regulatory approach and establish inspection and enforcement procedures. Because guidances are not regulations or laws, they are not enforceable, either through administrative actions or through the courts. An alternative approach may be used if such approach satisfies the requirements of the applicable statute, regulations, or both. For information on a specific guidance document, please contact the originating office.